Cytomegalovirus (CMV) pneumonia in the setting of nontransplantation patients is a rarity. We present a case of CMV pneumonitis in a woman with stage IV breast cancer, with brain metastases, receiving both chemotherapy and systemic corticosteroids. A review of the literature reveals this as a unique case.
Introduction
We report the successful treatment of a case of cytomegalovirus (CMV) pneumonia complicating chemotherapy and corticosteroid therapy for metastatic breast cancer, and discuss the management of CMV pneumonia. Cytomegalovirus infection is well-documented in immunocompromised patients, in particular following bone marrow and organ allotransplantation, and acquired immune deficiency syndrome. It has also been reported in the setting of autologous stem cell transplantation. Symptomatic disease is associated with a high mortality rate. This case report is of note for two particular reasons; one being the presence of dual pathology of breast cancer and cytomegalovirus pneumonia in a patient on standard dose chemotherapy and steroids, and the other being the successful treatment of the pneumonia.
Case report
A 45-year-old woman presented with a two week history of progressive diplopia and on physical examination was found to have a 2 cm breast mass and ipsilateral palpable axillary nodes. Biopsy of the axillary nodes showed a high grade infiltrating ductal breast carcinoma which was estrogen receptor negative. A CT brain scan revealed cerebellar and meningeal metastases ( Figure 1 ). Chest X-ray, ultrasound scan of liver and bone scan were normal. She was previously in good health and was on no medications.
She was married with four children and was a lifelong non-smoker. Her alcohol consumption was less than four units per week. She had no family history of cancer.
She was initially treated with intravenous dexamethasone 8 mg tid by the admitting physicians, and whole brain radiotherapy (30 Gy in 10 fractions). The steroid dose was then reduced over three weeks to a maintenance of 4 mg BID orally. Her neurological symptoms resolved. One month after her initial presentation she was started on combination chemotherapy with vinblastine (4.5 mg/m 2 day 1), doxorubicin (45 mg/m 2 day 1), and thiotepa 12 mg/m 2 day 1) on a 21 day cycle [1] . This regimen was selected as both vinblastine and thiotepa cross the blood-brain barrier, and in comparison to adriamycin-containing regimens, is as efficacious. Two weeks after the first cycle of chemotherapy she was admitted to the hospital with increasing dyspnoea and Figure 1 . CT of brain demonstrating metastatic lesion within the right hemisphere of the cerebellum. a non-productive cough. A chest radiograph revealed bilateral patchy consolidation with some collapse in the left base consistent with pneumonia. There was no evidence of neutropenia. She was treated empirically with intravenous cefotaxime 2 g intravenously daily for six days with moderate symptomatic improvement. She was discharged on cefpodoxime 200 mg BID to complete a further week of therapy.
When the patient presented for the second cycle of chemotherapy (two months after the start of treatment with steroids) she was dyspnoeic on minimal exertion. She was recommenced on dexamethasone at 4 mg BID orally by the admitting physicians. At this time her white cell count was 8.9 x 10 9 /l (3.5-11.0) with absolute neutrophil count 7.5 x 10 9 /l (2-7.5), lymphocytes 1.2 x 10 9 /l (l-3.5) and monocytes 0.1 x 1O 9 /1 (0.2-1.0). Arterial blood gases estimation on 28% oxygen showed pO 2 = 6.3 kPa, pCO 2 = 5.5 kPa, O 2 saturation = 86%. A subsequent chest X-ray showed a more diffuse interstitial infiltrate consistent with either Pneumocystis carinii pneumonia (PCP) or lymphangiitis carcinomatosa. In view of her compromised respiratory status she was transferred to our unit for combined pulmonary/oncological management. Empiric treatment with cotrimaxazole 1.25 ml/kg/day was initiated until PCP could be outruled. Her steroids where stopped following a satisfactory synacthen test of adrenal function.
Fiber-optic bronchoscopy was performed and was normal apart from moderate edema of the endobronchial mucosa. Bronchial brushings were normal, failing to show any malignant cells or viral inclusion bodies. Grocott's stain for Pneumocystis carinii was negative. Bronchoalveolar lavage was however positive for CMV. CMV complement fixation was positive at a titre of 1/256. CMV-specific IgM was positive, whilst CMVspecific IgG was negative. Both throat washings and peripheral blood buffy coat were positive for the DEAFF (detection of early antigen fluorescent foci) test.
Treatment with intravenous ganciclovir 330 mg (5 mg/kg) i.v. bid was commenced. The patient improved rapidly, both clinically and radiologically. The treatment was continued for a total of 14 days after which the patient was discharged home well and asymptomatic. There were no further episodes of CMV pneumonitis in her clinical course.
Discussion
CMV pneumonia in the setting of non-transplantation patients is a rarity. We performed an extensive review of the literature using both Cancerlit and Medline from 1966 to 1998 using the terms cytomegalovirus, pneumonitis, breast cancer, chemotherapy, dexamethasone, and steroids. From the literature search we identified this case presentation as a first report of CMV pneumonitis occurring in a breast cancer patient on standard dose chemotherapy. The recent use of high dose steroids probably had a significant role in the development of the CMV pneumonitis, despite that lack of lymphopenia. This patient's course was characteriszed by the development of CMV pneumonitis following commencement of chemotherapy for stage IV breast cancer. It is highly unusual for this form of infection to become symptomatic outside of a transplantation or AIDS settings. Symptomatic disease in these settings has a high mortality.
Prior CMV infection can be detected in up to 50%-80% of immunocompetent hosts. CMV is a member of the herpesvirus family, with the ability to generate both persistent or latent infections. Reactivation is believed to be the most common pathogenesis of infection in the immunocompromised state [2] . Studies in animal models and immunocompromised patients implicate deficiencies in Class I MHC-restricted CD8* CMV-specific cytotoxic T lymphocyte responses in the progression of CMV infection, and progression to pneumonia [3] .
CMV pneumonia is a well recognised late complication occurring one to three months after allogeneic bone marrow transplantation. Untreated infection usually leads to rapid respiratory failure and death. With the use of anti-viral prophylaxis following allogeneic bone marrow transplantation a later occurrence of CMV pneumonia (i.e., three to nine months after transplantation) has become more common. Risk factors associated with the development of CMV infection include CMV seropositivity, the use of total body irradiation, increasing age, and the appearance of acute graft-vs.-host disease. Despite modern therapies the mortality rate is about 50% [4] [5] [6] [7] .
In the setting of autologous bone marrow transplantation CMV pneumonia incidence rates are in the range of 0.8% to 7%. The prognosis is as poor as in the allogeneic setting. Following solid organ transplantation infection rates with CMV are in the 50% range, but the development of CMV pneumonia tends to be more subacute. In the setting of HIV infection, CMV pneumonitis tends to be a late feature, especially when CD4 counts fall below 50/ml [6] , In a retrospective, autopsy-based study, investigators at MD Anderson found an incidence of 2.2 cases of CMV pneumonia per 1,000 autopsies in non-transplanted cancer patients. CMV pneumonia was defined by the following histopathologic criteria: (a) characteristic intranuclear inclusions with surrounding necrosis and/or inflammation and (b) the absence of any other pathogen in the same histologic section. Immunohistochemical studies were then performed on these cases to confirm the diagnosis. This review included 675 autopsies of breast cancer patients. In this series, 20 of 9,029 patients were diagnosed with CMV pneumonitis. All had received chemotherapy; 15 had received steroids. The doses and duration of therapy were not specified. The indications for the steroid therapy wereas not outlined in the paper. Thirty percent of the CMV pneumonia cases were in patients with solid tumors, but none of these had breast cancer [8] .
Generalized CMV infection is most often identified in conjunction with other morphologically defined infections. This subset of patients usually have relatively far-advanced neoplastic states [9] . It has been suggested that the simultaneous detection of CMV with other infectious agents represents dissemination secondary to a final deterioration in host defenses rather than simultaneous primary infections with multiple agents [2] . Evidence from autoimmune-mediated diseases requiring cytotoxic agents indicate that these drugs may lead to asymptomatic CMV shedding [2] . In studies on the effects of adjuvant chemotherapy on CMV isolation in breast cancer patients, lymphopenic effects have been demonstrated, in addition to increased shedding of CMV [10] . Alkylating agents have been particularly associated which an increased incidence in reactivation of CMV infections. Once shedding occurs, it can persist for months to years. As illness appears more closely related to the appearance of antibodies than to the onset of virus shedding, it is believed that the host response to the virus has a key role in the nature of the disease induced [2, 4, 5, 11] .
The diagnosis of a viral pulmonary infection is defined according to three key factors as outlined in Table 1 . Unlike bacterial detection, where its detection may represent coloniszation, the presence of virus indicates infection, though not necessarily disease. Disease is determined by the degree of inflammatory response and the degree of organ dysfunction. Excretion of herpesviruses, such as CMV, can occur without pneumonia, and isolation of the virus from remote sites to the lungs does not necessarily confirm it as the cause of the pneumonia [12, 13] .
Detection of the virus in the lung tissue is the most convincing evidence of viral etiology of a pneumonia. Nasopharyngeal excretion of the virus strongly suggests, but is not conclusive evidence of a viral etiology for the disease. Minimal evaluation should include a bronchoscopy with bronchoalveolar lavage (BAL), a procedure which has replaced the need for open lung biopsy in most cases. The samples should be assessed by routine cytology and centrifugation culture [12, 13] . It is important to note that BAL samples may detect CMV in patients without symptoms or signs of infection, thereby running the risk of overdiagnosis. This effect is amplified with the use of polymerase chain reaction for the detection of CMV DNA in lavage samples [14] [15] [16] .
Optimal management of CMV pneumonitis in the setting of neoplasia has been based predominantly on the results of studies in the setting of bone marrow transplantation [17] [18] [19] . The mortality rate still remains greater than 50% despite recent advances in therapy, particularly if there is established hypoxaemia, and diffuse bilateral infiltrates on chest X-rays [7] . Ventilator dependence at any point in the course of the CMV pneumonitis is associated with nearly inevitable fatality [20] . The earlier the initiation of specific anti-CMV therapy the greater the potential therapeutic effect.
Reports from numerous centers in post-transplantation-associated CMV pneumonitis indicate improved 
Features defining viral pulmonary infection
• Clinical evidence pneumonia.
• Identification of virus from lung or blood samples.
• Causal link between the isolated virus and the pulmonary disease. Table 2 . Characteristics of ganciclovir and treatment-related issues.
Characteristics ofganclovir
• Synthetic nucleoside analog of 2'-deoxyguanosine.
• Completely inhibits viral DNA polymerase.
• May be incorporated within viral DNA to cause early termination of DNA replication.
• Requires intravenous administration as less than 7% is absorbed following oral administration.
• Only 2% to 3% protein bound.
• Preferentially concentrates within CMV-infected cells due to the action of cellular kinases that convert it to ganciclovir triphosphate.
• Greater than 90% is excreted unchanged, predominantly via glomerular filtration.
• Intramuscular injections are contraindicated.
Toxic ily profile ofgan ciclo vir
• Haematological: 40% of patients develop some form of haematologic toxicity including neutropenia on thrombocytopenia. Cell counts usually recover within three to seven days of stopping the agent. CNS: Confusion, seizures, dizziness, headaches. GI: nausea, vomiting, diarrhoea. GU: Haematuria. CVS: arrhthymias, hypotension, hypertension. Derm: rash, alopecia, pruritis.
Points to consider
• Dose reductions of ganciclovir required in those with renal impairment.
• Administer drug over a one-hour period; never as a bolus.
• Nuetropenia is most likely to occur after about 10 days of therapy.
• Alert patient to the symptoms and signs of thrombocytopenia.
survival rates with the combination of high dose intravenous gammaglobulin and specific anti-viral therapy with ganciclovir [4, [17] [18] [19] . However, others have failed to confirm these results. It has been recognized that short term therapy (less than 14 days) is associated with high recurrence rates. In transplantation patients, ganciclovir alone or acyclovir with immunoglobulin is less effective [21] [22] [23] [24] . Ganciclovir alone is appropriate in the non-transplant setting. Foscarnet is a reasonable alternative in those with pre-existing myelosuppression, but is associated renal toxicity. No randomised trials comparing treatment with ganciclovir versusand foscarnet have yet been performed. Table 2 outlines some important characteristics of ganciclovir.
The recognition and avoidance of predisposing factors is important, particularly in the high risk post-transplant patient. Serostatus is the most important factor determining choice of prophylactic regimens. It is important to consider the potential infectivity of blood products which may be required during the period of required therapy. The use of seronegative blood products helps prevent CMV disease in seronegative patients, whilst chemoprophylaxis has been most useful in seropositive patients. Interest in prevention through vaccination is stimulated from work in organ transplantation, and pregnant seronegative women who develop a primary CMV infection during pregnancy [22] .
Conclusion
This case identifies a unique clinical situation with CMV pneumonitis in the setting of standard dose chemotherapy plus steroid therapy for metastatic breast cancer. Whether the initial respiratory symptoms were in part due to a developing CMV pneumonitis is unclear. At that point in her therapy she was on prolonged high doses of steroid medication. The symptomatic response during the initial respiratory presentation with antibiotics makes it unlikely that dual bacterial and viral pathologies where involved.
As the infiltrate on the second presentation had a pattern suggestive of PCP, and the patient had been on significant doses of steroid, a non-bacterial cause was considered in the differential diagnosis. She was commenced on cotrimaxazole empirically until a definitive diagnosis could be made. Once the diagnosis of CMV pneumonitis was established ganciclovir was commenced. The patient responded well to ganciclovir, with full recovery from the pneumonic process.
The combined used of ganciclovir and immunoglobulin has only been shown to have a clinical advantage in post-transplantation patients. The combination has not been shown to be more efficacious outside of this setting. It was for this reason than monotherapy with ganciclovir was chosen.
Steroid therapy probably contributed significantly to the development of the CMV pneumonia in this case, despite the normal lymphocyte counts. Though high dose steroid therapy has been shown to be associated with CMV colitis, this is not the case with CMV pneumonitis [25] . Other case reports of CMV pneumonitis with co-existing cytotoxic agents and steroids are from the connective tissue disease literature where prednisone with cyclophosphamide, and steroid and methotrexate were administered [26, 27] .
Whilst corticosteroids are believed to be insufficient by themselves to enhance CMV infection, they may play a subsidiary role in producing CMV disease. Rubin et al. pointed out that rates of CMV disease have declined decreased compared with the over time with the use of modern immunosuppressants compared with the period when corticosteroids were used in much higher doses as an adjunct to azathioprine in renal transplant patients [28] . It is therefore likely that the steroid therapy in our patient facilitated the development of the CMV pneumonia. As prolonged steroid therapy has multiple negative side-effects, it is important to wean patients off corticosteroids as soon as possible following successful cranial irradiation. Potential viral etiologies should therefore be considered even in non-transplanted cancer patients with pneumonia, particularly if steroids are a component of their therapy.
